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ABSTRACT 
Angioadaptation is the ability of capillaries to adapt to physiological changes. 
This is influenced by interactions between endothelial cells and supporting cells such as 
myofibroblasts. We examined a possible pro-angiogenic paracrine interaction between 
primary human dermal microvascular endothelial cells (HDMECs) and newly identified 
myofibroblast (MyoFib) progenitors in human skeletal muscle, and how this interaction 
may be altered under hyperglycemic conditions. Human skeletal muscle Myofib 
progenitor cells (CD90+) were sorted by FACS and differentiated into MyoFib using 
TGFβ under normo- (NG) or hyperglycemic (HG) conditions. The expression level of 55 
angioadaptive proteins was measured by proteome array in the conditioned media. 
HDMECs were then treated with the conditioned media. VEGF-A, TSP-1 mRNA 
expression, and VEGF-A, TSP-1, p38, p-p38, and p-VEGF-R2 protein levels were 
measured by qPCR and western blot respectively. HDMEC migration was evaluated in 
the Boyden Chamber assay. HDMECs were also subjected to chronic HG and 
analyzed. The secretome from differentiated MyoFibs was enriched in pro-angiogenic 
factors compared to CD90+ cells. VEGF-A and p-p38 expression was increased in 
HDMECs when treated with MF secretome and their migration was stimulated. In 
contrast, CD90+ cell differentiation under HG resulted in decreased pro-angiogenic 
factor secretion in MF secretome and reduced EC migration. HDEMCs under HG had 
reduced migration and p-VEGF-R2. MyoFib exert some pro-angiogenic stimulation on 
HDMECs compared to progenitor cells. This pro-angiogenic effect is attenuated when 
cell differentiation occurs under HG.  
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LITERATURE REVIEW 
Introduction    
The microcirculatory system is critical to the maintenance and health of all 
tissues in the human body. It relies on capillaries, the smallest vessels, responsible for 
the exchange of oxygen, nutrients, and metabolic waste between the blood and cells. 
The skeletal muscle tissue is not an exception, and its capillary network has been well 
established as a key determinant of its function (Hudlicka, Brown, & Egginton, 1992). 
Capillaries are composed of a single layer of endothelial cells. They serve as 
ideal sites for the exchange of oxygen and waste due to the minimal diffusion distances 
they provide. August Krogh was the first to suggest that each capillary can supply 
oxygen to a given cylindrical area of tissue surrounding the capillary in question (Krogh, 
1919). Although Krogh’s idea has since been expanded and elaborated on, the notion 
that a capillary supplies a fixed area still serves as the foundation for models of capillary 
function today (Egginton & Gaffney, 2010). Consequently, capillary networks are 
consistently aiming to parallel changes that occur within the tissue they supply.  
Over the last few decades, the role and complexity of the microcirculatory system 
has been uncovered and defined. This has changed the dogma that capillaries simply 
formed a permissive barrier to instead the notion that their organization is dynamic, 
complex, and very reactive to changes within the microenvironment. Such functional 
plasticity can lead to the maintenance of capillaries, their regression, or their growth 
(angiogenesis), which is now referred to as angio-adaptation (Olfert & Birot, 2011; 
Roudier et al., 2010). Angiogenesis is a complex process, requiring the coordination of 
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a large number of signals and cell types. At the onset of sprouting angiogenesis, 
endothelial cells are liberated from the surrounding basement membrane. The 
extracellular matrix (ECM) requires proteolytic breakdown mediated by matrix 
metalloproteinases (MMPs) (Potente, Gerhardt, & Carmeliet, 2011). This allows 
freedom for endothelial cells to proliferate and migrate under the influence of angio-
adaptive signals. Three major mechanisms are involved in endothelial migration during 
angiogenesis, including; chemotaxis, the directional migration toward a concentration 
gradient of soluble factors, haptotaxis, the directional migration toward a gradient of 
fixed ligands, and mechanotaxis, the directional migration generated by mechanical 
forces (Lamalice, Le Boeuf, & Huot, 2007). Vessel fusion, maturation, and stabilization 
takes place as new ECM components are deposited, and mural cells such as pericytes 
are recruited to the vessels (Carmeliet, 2003; Potente et al., 2011).  
  Angiogenesis plays a central role during embryogenesis, organ development, 
and responses to physiological challenges such as exercise. Insufficient vessel 
maintenance or growth is implicated in numerous conditions such as stroke, myocardial 
infarction, heart failure, and diabetes. Alternatively, excessive vessel growth can lead to 
cancer, ocular disorders, and various inflammatory disorders (Carmeliet & Jain, 2011; 
Hudlicka et al., 1992; Potente et al., 2011). Therefore, an appropriate and well 
coordinated angio-adaptive response is critical across the continuum of pathological to 
physiological challenges.  
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Angioadaptive Factors  
 A large myriad of angio-adaptive factors have been discovered to date. It is 
important to consider that the direction of angio-adaption (regression, growth, or 
stabilization) is determined by a delicate balance between pro- and anti-angiogenic 
factors. Changes on either side of the balance will ultimately shift the angio-adaptive 
characteristics of the micro-environment surrounding a given capillary network [Figure 
1]. While there are numerous factors that fall on each side of the angio-adaptive 
balance, the pro-angiogenic Vascular Endothelial Growth Factor (VEGF) and the anti-
angiogenic Thrombosondin-1 (TSP-1) are two of the most well characterized and 
extensively studied (Olfert & Birot, 2011). 
Vascular Endothelial Growth Factor is a 35 – 45 kDa homodimeric protein that 
was initially discovered because of its ability to increase permeability of blood vessels, 
and was subsequently named Vascular Permeability Factor (VPF) (Senger, Perruzzi, 
Feder, & Dvorak, 1986). VEGF was shortly after isolated by Leung and colleagues, and 
has since been the dominant pro-angiogenic factor in angiogenesis research (Leung, 
Cachianes, Kuang, Goeddel, & Ferrara, 1989). There are currently five known members 
in the VEGF family, including placenta growth factor (PIGF), and VEGF-A through 
VEGF-D. VEGF-A is believed to be the most influential in angiogenesis (Egginton, 
2009). It has been shown that alternative splicing from the eight exon VEGFA gene can 
lead to different isoforms of VEGF-A in humans, differentiated by their varying molecular 
weights. The first isoform described, VEGF-A165, is the predominant isoform of VEGF-A, 
and has been extensively investigated (Ferrara, Gerber, & LeCouter, 2003). Between 
1989 and 2003, other isoforms including VEGF-A121, VEGF-A145, VEGF-A148, VEGF-A183, 
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VEGF-A189, and VEGF-A206 were identified and shown to be generated by alternative 
splicing of exons 6 and 7 (Harper & Bates, 2008) . More recently, another alternatively 
spliced form of VEGF-A was reported, and termed VEGF-Axxxb. These isoforms are 
believed to have lower affinities for VEGF receptors, competing with VEGF-A to 
negatively regulate angiogenesis (Harper & Bates, 2008; Shibuya, 2013).  
VEGF-A is produced by endothelial cells, and host tissue cells such as skeletal 
muscle. VEGF-A plays a number of critical roles in angiogenesis, including stimulating 
endothelial cell proliferation, migration, and survival (Egginton, 2009; Ferrara, 2004). 
While VEGF is acting on endothelial cells from a number of paracrine sources, it also 
appears that autocrine VEGF stimulation is required for vascular homeostasis (Lee et 
al., 2007). 
VEGF acts through a family of tyrosine kinase receptors, composed of four main 
regions; the extracellular domain that binds the ligand, transmembrane domain, tyrosine 
kinase domain, and carboxyl terminal region (Ferrara et al., 2003; Shibuya, 2006). 
There are currently three known largely endothelial cell specific receptor tyrosine 
kinases. VEGF-Receptor 1 (VEGF-R1) or fms-related tyrosine kinase 1 (Flt-1), VEGF-
Receptor 2 (VEGF-R2) also known as kinase insert domain receptor (KDR) in the 
human and fetal liver kinase 1 (Flk-1) in the mouse, and VEGF-Receptor 3 (VEGF-R3) 
also known as (Flt-4). Although they have different biological roles, each VEGFR has an 
essential activity in angiogenesis, as VEGFR-1, VEGFR-2, and VEGFR-3 knockout 
mice are all embryonically lethal due to vascular defects (Lamalice et al., 2007).
 VEGF-A primarily exerts its effects through VEGF-R1 and VEGF-R2 (Koch & 
Claesson-Welsh, 2012; Shibuya, 2006). Although VEGF-R1 has a much stronger 
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affinity for VEGF, VEGF-R2 is the primary pathway for VEGF-A signaling in endothelial 
cells, with its activation leading to survival, proliferation, and migration responses 
(Egginton & Gaffney, 2010; Koch & Claesson-Welsh, 2012).  
Binding of VEGF-A to VEGF-R2 leads to receptor dimerization, and promotes 
auto/trans-phosphorylation of several sites on the VEGF-R2 intracellular domain (Koch 
& Claesson-Welsh, 2012). This further activates multiple intracellular transduction 
pathways through downstream mediators resulting in biological responses such as the 
mentioned proliferation, migration, survival, and permeability. For example, activation of 
tyrosine 1175 induces activation of the PI3K-AKT and ERK 1/2 pathways. Furthermore, 
tyrosine 1214 has been shown to activate the cell migration associated p38 MAPK 
pathway, which is tied to alterations in cell adhesion and actin dynamics, promoting cell 
migration (Koch & Claesson-Welsh, 2012; Lamalice et al., 2007; Olsson, Dimberg, 
Kreuger, & Claesson-Welsh, 2006; Rousseau, Houle, Landry, & Huot, 1997).   
Anti-angiogenic or angiostatic factors have garnered much less attention than 
their pro-angiogenic counterparts. One of the most widely studied and well 
characterized anti-angiogenic factors is Thrombospondin-1 (TSP-1). TSP-1 is a large 
(~450 kDa) multifunctional homotrimeric glycoprotein whose actions are targeted at 
inhibiting angiogenesis (Iruela-Arispe, Luque, & Lee, 2004; Olfert & Birot, 2011). 
Thrombospondin-1 is produced by endothelial cells, as well as smooth muscle cells, 
fibroblasts, neutrophils, and macrophages (Bornstein, 1992; Iruela-Arispe et al., 2004; 
Olfert & Birot, 2011).  TSP-1 is also found localized in the extracellular compartments of 
host tissues and organs, including skeletal muscle, cartilage, skin, and bone (Bornstein, 
1992; Iruela-Arispe et al., 2004) 
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 TSP-1 acts as an anti-angiogenic factor by inhibiting cell migration, and inducing 
endothelial cell apoptosis. These actions are mainly accomplished through 3 receptors; 
Cluster of Differentiation 36 (CD36), β1-integrin, and Cluster of Differentiation 37 
(CD37) (Bonnefoy, Moura, & Hoylaerts, 2008; Iruela-Arispe et al., 2004; Olfert & Birot, 
2011; Ren, Yee, Lawler, & Khosravi-Far, 2006). Receptors CD36 and β1-integrin both 
interact with VEGF-R2, forming complexes in the endothelial cell membrane, and 
appear to inhibit VEGF-A induced phosphorylation and activation of VEGF-R2 (Olfert & 
Birot, 2011; Zhang et al., 2009). TSP-1 has also been shown to inhibit angiogenesis 
without interacting directly with the endothelial cell. For example, TSP-1 can impair 
matrix metalloproteinase 9 (MMP-9) activation, therefore impairing VEGF-A release 
from the extracellular matrix, or directly bind to VEGF-A itself and promote its 
internalization and degradation (Olfert & Birot, 2011).  
Skeletal Muscle & Angio-adaptaion 
Skeletal muscle tissue makes up 40% of our body weight, and plays a key role in 
metabolic regulation and locomotion. Active muscles require increased supply of 
oxygen and nutrients, and removal of metabolic by-products (Hudlicka et al., 1992). 
Skeletal muscle angio-adaptation is tightly regulated by a balance between pro- and 
anti-angiogenic signals (Ferrara et al., 2003; Olfert & Birot, 2011). The previously 
detailed VEGF-A and TSP-1 are to date the most well characterized regulators of 
skeletal muscle angio-adaptation (Olfert & Birot, 2011). The use of transgenic animal 
models has shown that modulation of VEGF-A and TSP-1 affected muscle 
capillarization with direct functional consequences in terms of exercise capacity and 
performance. In 2006, Wager’s group showed muscle-targeted deletion of VEGF in 
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Figure 1. Angioadaptation as a balance between pro- and anti-angiogenic 
factors. The direction of angioadaptation is determined by a balance between pro- and 
anti- angiogenic factors. A predominance of pro-angiogenic signals such as VEGF will 
lead to a pro-angiogenic microenvironment, promoting capillary growth. A 
predominance of anti-angiogenic factors such as TSP-1 will instead promote capillary 
regression. When angio-adaptive factors are evenly balanced, the capillary network is 
maintained. It is important to note that changes can occur on either side of the balance 
independently, or accompany each other. 
mice resulted in a loss of two-thirds of the muscle capillaries, and had a severe impact 
on exercise capacity (Wagner, Olfert, Tang, & Breen, 2006). This work was followed up 
by studies that demonstrated muscle specific VEGF deficiency reduces exercise 
endurance, and that myocyte VEGF is required for exercise induced skeletal muscle 
angiogenesis (Olfert et al., 2009; Olfert, Howlett, Wagner, Breen, & Virginia, 2010). 
From an anti-angiogenic signaling perspective, Malek and Olfert have shown that global 
deletion of TSP-1 increases both skeletal muscle capillarity and exercise capacity 
(Malek & Olfert, 2009).  
Physical exercise is a physiological stress that considerably challenges the 
balance between the blood supply and the myofibers' metabolic needs, and that 
therefore strongly stimulates skeletal muscle angiogenesis (Egginton, 2009). While one 
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single acute bout of exercise will alter the angio-adaptive balance at a molecular level, 
chronic exercise (i.e. training) will lead to the formation of new capillaries (Egginton, 
2009). Conversely, under chronic pathological conditions such as obesity, diabetes, 
peripheral vascular disease (PVD), and chronic obstructive pulmonary disease (COPD), 
the angiogenic ability of the muscle is impaired and some capillary rarefaction can occur 
(Gouzi et al., 2013; Haas, Lloyd, Yang, & Terjung, 2012; Kivelä et al., 2008; Olfert et al., 
2009). Muscle capillary rarefaction is not limited to pathological conditions, and can also 
occur in a physiological context such as muscle inactivity or detraining. Training-induced 
angiogenic remodeling was reversible in rats with 1 week of detraining, following a 10 
week endurance training program (Malek, Olfert, & Esposito, 2010). Hypokinesia 
provides another example of non-pathological capillary rarefaction, as rats subjected to 
9 day hindlimb unloading experience capillary rarefaction in the soleus muscle (Roudier 
et al., 2010).   
What is striking about the research on skeletal muscle angio-adaptation is that 
the focus has been so far mostly restricted to the tissue level (i.e. the whole muscle) or 
to skeletal muscle endothelial cells alone. While the myofibers may be significant 
contributors of angiogenic stimuli during exercise conditions, the same may not be true 
under other physiological or pathological settings. Very few studies have addressed the 
role of other cell type contributors. Surrounding and supporting cell types also produce 
molecules that influence the microenvironment of a given capillary network (Davis & 
Senger, 2005; Gaengel, Genové, Armulik, & Betsholtz, 2009; Olfert & Birot, 2011; 
Potente et al., 2011). As noted earlier, VEGF-A and TSP-1 are secreted by a number of 
cell types in addition to the endothelial cell and myofibers, including fibroblasts, immune 
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cells, mural cells, and other supporting cell types (Bornstein, 1992; Ferrara et al., 2003; 
Olfert & Birot, 2011). While these paracrine interactions are essential, physical 
interactions between endothelial cells and various surrounding cell types are also 
paramount to the survival, growth, and maturation of capillaries. For instance, the 
stromal cells, which secrete and organize the extracellular matrix (ECM), provide 
structural support and organizational stability to the capillaries. Endothelial cells require 
adhesion to the ECM for migration, proliferation, and  survival (Davis & Senger, 2005). 
Thus, the pro-angiogenic activity of endothelial cells is also highly dependent on 
paracrine, as well as physical interactions with their surrounding cells. 
Hyperglycemia and the Microvasculature 
 Hyperglycemia is a hall mark of type I and type II diabetes (Bakker, Eringa, 
Sipkema, & van Hinsbergh, 2009). In physiological conditions, endothelial cells 
encounter blood glucose levels. in the range of ~3.6-5.8 mM, and  cells exposed to 
glucose levels greater than 10 mM, in vitro or in vivo as in diabetes mellitus, are 
considered be in a high glucose condition (Popov, 2010). Diabetes is accompanied by a 
multitude of complications that negatively impact the integrity of the microvasculature 
and angiogenic activity (Beckman, Creager, & Libby, 2002; Martin, Komada, & Sane, 
2003). High glucose levels disrupt endothelial cell homeostasis, leading to endothelial 
dysfunction and detrimental changes in the microvasculature, including  (Popov, 2010). 
In diabetogenic conditions, angiogenic responses are enhanced in some tissues (retina 
and kidney), while they are impaired in other tissues, leading to defective wound 
healing, peripheral circulation, and coronary circulation (Moriya & Ferrara, 2014). 
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The Myofibroblast 
Myofibroblasts were first identified as modified fibroblasts that expressed 
features of smooth muscle in the granulation tissue of healing wounds (Gabbiani, Ryan, 
& Manjo, 1971). Following injury, inflammatory cells and platelets secrete a host of pro-
inflammatory cytokines such as transforming growth factor beta (TGF-β), which induce 
the differentiation of fibroblasts into myofibroblasts (Hinz, 2007; Tomasek, Gabbiani, 
Hinz, Chaponnier, & Brown, 2002). Research has since been heavily focused on their 
role during wound healing. Myofibroblasts contribute to the wound healing process by 
producing a contractile force aimed at closing the wound margins. This ability to 
generate contractile forces relies on the expression of alpha smooth muscle actin 
(αSMA) (Hinz, 2007; Tomasek et al., 2002). Concurrently, myofibroblasts also 
contribute to the wound healing process by secreting several components of the ECM 
such as collagens of types I,III, IV, and V, thereby assisting in tissue remodeling and 
wound resolution (Hinz, 2007). Cells with myofibroblastic characteristics have been 
observed in a wide range of tissues and organs, including the skeletal muscle, liver, 
lung, and kidney among others (Dulauroy, Di Carlo, Langa, Eberl, & Peduto, 2012; Hao 
et al., 2006; Hinz et al., 2007; Li & Huard, 2002; Tomasek et al., 2002).  
Although myofibroblasts play an undeniable role in successful healing, 
perpetuated activity can lead to negative consequences. Persisting infection, genetic 
disorders such as muscular dystrophy, or ageing, can lead to sustained chronic 
inflammation causing persistence of myofibroblast activity. This can lead to excessive 
deposition of ECM components and a stiffening and/or scarring of tissues, termed 
fibrosis (Hinz, 2007; Wynn, 2008).  
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Myofibroblast precursor cells are recruited from different sources depending on 
the tissues to be remodeled. The main progenitor population appears to be locally 
residing fibroblasts, however, pericytes, smooth muscle cells, bone marrow derived 
circulating cells, and epithelial cells have been shown to serve as important 
myofibroblast precursor populations (Hinz et al., 2007). 
Myofibroblasts and Angiogenesis 
Recent studies have pointed out an important role for the myofibroblast in 
angiogenesis (Daigle, Despatis, & Grenier, 2013). This is strengthened by the fact that 
pericytes, ubiquitous perivascular cells, have recently been shown to be an important 
cell progenitor population for myofibroblasts, and providing explanation of their 
presence in the vicinity of capillaries within virtually all vascularized tissue (Desmoulière, 
Guyot, & Gabbiani, 2004; Greenhalgh, Iredale, & Henderson, 2013; S.-P. Wong et al., 
2015). For example, in addition to fibroblasts, activated pericytes have been shown to 
detach from local capillaries, migrate to sites of injury, and differentiate into 
myofibroblasts (S.-P. Wong et al., 2015). For this reason, studies have examined the 
possible paracrine relationship between endothelial cells and myofibroblasts.  
Endothelial cells have been to shown to proliferate faster when incubated with media 
conditioned by myofibroblasts (Nicosia & Tuszynski, 1994; Villaschi S, 1994). Cardiac 
and tumor associated myofibroblasts also produce and release various pro-angiogenic 
cytokines such as the VEGF-A (Chintalgattu, Nair, & Katwa, 2003; Vong & Kalluri, 
2011). Interestingly, the production of VEGF-A by dermal myofibroblasts is significantly 
higher than from undifferentiated fibroblasts (Mayrand et al., 2012). This reinforces the 
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idea that myofibroblasts could play an important angio-adaptive role by modulating pro- 
and anti-angiogenic signals toward the endothelial cell.  
 
This paracrine relationship can also be viewed from the perspective of the 
endothelial cell. For example, endothelial cells secrete endothelin-1 (ET-1), which 
promotes the differentiation of dermal fibroblasts into myofibroblasts during wound 
healing (Hinz, 2007; Leask, 2010; Villaschi S, 1994). Thus, these works strongly point 
out the existence of an active and reciprocal paracrine relationship between the 
myofibroblast and endothelial cell populations [Figure 2].  
Several studies also suggest the existence of a physical relationship between 
these two cell types (Koike et al., 2004; Mayrand et al., 2012). Using co-culture 
experiments, it has been shown that mesenchymal cells and endothelial cells can lead 
to the formation of vascular tubes that are larger and at a higher density than tubes 
Figure 2. Reciprocal angio-adaptive relationship between the myofibroblast and 
endothelial cell. Myofibroblasts and endothelial cells appear to exist in a reciprocal 
paracrine and physical relationship that may have consequences on the functionality and 
viability of each cell type. Such interaction may be disrupted under pathological 
conditions. 
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obtained with endothelial cells only (Black, Berthod, L’heureux, Germain, & Auger, 
1998; Koike et al., 2004; Villaschi S, 1994). Interestingly, the stability of these vascular 
tubes was also maintained for a longer period of time compared to tubes formed in 
cultures of endothelial cells alone (Mayrand et al., 2012; Nicosia & Tuszynski, 1994). It 
was also shown that when dermal myofibroblasts were co-cultured with endothelial 
cells, they maintained their differentiation into myofibroblasts for a longer period of time 
as shown through the expression of αSMA (Mayrand et al., 2012). In addition, the 
physical interaction between the two cell populations also promotes the production of 
type IV collagen from myofibroblasts, which is found in the supportive basement 
membrane of the vessels, providing vessel stability (Davis & Senger, 2005; Villaschi S, 
1994). An in vivo study by Hansen et al. showing stretch-induced angiogenesis in 
skeletal muscle demonstrated a higher density of <10µm diameter vessels with αSMA-
positive cells with respect to controls. Microscopic analyses provided evidence that 
growth of vessels in stretched muscles appeared to involve the migration of cells in the 
vicinity of capillaries, some of which were embedded in the capillary basement 
membrane. These mesenchymal cells, believed to be fibroblasts, migrated towards the 
capillaries before transforming into αSMA expressing pericytes or smooth muscle cells 
(Hansen-Smith, Egginton, Zhou, & Hudlicka, 2001). It is worth hypothesizing if these 
migrating cells share myofibroblastic characteristics. 
Transformation of fibroblasts/pericytes into myofibroblasts involves the presence 
of other inflammatory factors such as Sphingosine 1-phosphate (S1P), a bioactive 
sphingolipid derived from sphingomyelin. S1P is implicated in the regulation of number 
of biological functions, including cell growth, migration, and inflammation. S1P acts 
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mainly through five G-protein coupled receptors, named S1PR1 - R5.  In fibroblasts, SIP 
and S1PR1 are involved in cell migration and differentiation into myofibroblasts (Hamidi, 
Schäfer-Korting, & Weindl, 2014). Interestingly, it was demonstrated that S1P could 
accelerate the neo-vascularization process in diabetic mice and improve wound healing 
(Kawanabe, Kawakami, Yatomi, Shimada, & Soma, 2007). Although known to favour 
VEGF-A secretion by endothelial cells (Heo, Park, Kim, Kim, & Oh, 2009; Sun, Wei, Xu, 
Xu, & Zhang, 2010), it is appealing to propose that it could exert a similar effect in 
myofibroblasts that also secrete VEGF-A. Thus, this physical relationship between 
endothelial cells and myofibroblasts seems to play an equally important role as the 
paracrine cross-talk in an angiogenic context. Hence, identifying and targeting proper 
progenitors or differentiated myofibroblasts could provide benefits to angiogenesis. 
 
Mesenchymal Stem Cells 
 Adult human stem cells have been derived from numerous tissues. They usually 
lack tissue specific characteristics, but can differentiate into specialized cells with 
phenotypic differences from their original precursor. It is generally thought that these 
stem cells residing in adult tissues serve as reservoirs, which can be mobilized and 
differentiated in response to the signals produced by wound and disease conditions   
(Barry & Murphy, 2004; Krampera, Pizzolo, Aprili, & Franchini, 2006).   
 Mesenchymal stem cells (MSCs) were first identified by Friedenstein and 
Petrakova in 1966, who isolated bone-forming progenitor cells from rat marrow 
(Friedenstein, Piatetzky-Shapiro, & Petrakova, 1966). Numerous groups have confirmed 
and expanded on Friendenstein’s initial findings, showing that human bone derived 
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MSCs have the ability to differentiate into numerous cell types such as osteoblasts, 
chondrocytes, adipocytes, and myoblasts (Barry & Murphy, 2004; Murray et al., 2014). 
MSCs were traditionally harvested from bone marrow, but have now been isolated from 
a number of human tissues including fat, skin, dental pulp, and muscle (Murray et al., 
2014). Until now, most of the work that has been done aimed to characterize and 
expand these cells in vitro. Therefore, much of the current knowledge of MSCs is based 
on characterization and observations of behavior in culture (Murray et al., 2014).  
 Variations in methods of isolation, culture, and assays used to examine MSCs 
have made standardization of the nomenclature used in the field difficult. In 2006, the 
International Society for Cellular Therapy (ISCT) proposed the minimum criteria 
required to define MSCs (Dominici et al., 2006). They stated that cells must be plastic 
adherent, and must express cell surface antigens CD105, CD73, and CD90. 
Furthermore,  these cells must not express the cell surface antigens CD45, CD34, 
CD14, CD11b, CD79α, CD19, or HLA-DR. Lastly, isolated cells are required to undergo 
tri-lineage differentiation into osteoblasts, adipocytes, and chondroblasts under defined 
culture conditions (Dominici et al., 2006; Murray et al., 2014). As discussed, MSCs have 
been shown to differentiate into other cell types while expressing other markers then 
those required in the ISCT guidelines. However, these ‘extra’ conditions are not 
required to define true MSCs (S.-P. Wong et al., 2015). Importantly, MCSs isolated from 
different organs and tissues exhibit unique features. The uniformity of MSCs from 
different origins has not been consistently demonstrated, even if they fulfill the ISCT 
criteria. MSCs from different origins have displayed differences in immunophenotype 
and secreted cytokine profile. Most of our understanding of MSCs is based on ex vivo 
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culture, and their in-vivo counterparts have remained elusive. Therefore, their native 
origin and physiological roles in vivo have been overlooked (Murray et al., 2014).  
 
CD90+ Skeletal Muscle Derived Myofibroblast Progenitor 
Dr. Grenier’s group, at the University of Sherbrooke, have recently identified and 
characterized a novel human skeletal muscle resident myofibroblastic stem cell 
(Downey et al., 2015). These CD105, CD73, CD90 positive cells (referred to as CD90+ 
progenitors) are capable of differentiating into myofibroblasts upon stimulation with 
transforming growth factor beta (TGFβ). Myofibroblastic differentiation of these 
progenitors was confirmed by measuring the expression of αSMA and collagen type I at 
the gene and protein levels, as well as cell functionality through contractility. Seeing as 
how most research examining the relationship between myofibroblasts and endothelial 
cells has been limited to myofibroblasts of dermal and tumor origin, we saw the 
identification of these skeletal muscle progenitors as an exciting opportunity to explore 
their possible relationship with endothelial cells.  
 
Conclusion 
 As discussed, much of the research in skeletal angiogenesis has been limited to 
looking at the whole muscle, or the endothelial cells themselves. Much less work has 
been done examining other surrounding and supporting cell types that could play an 
important role in influencing the microenvironment around a capillary, and the roles of 
stromal cells in angiogenesis has received too little attention. Concurrently, 
17 
 
myofibroblasts have been shown to play an important role in angiogenesis, however, 
nearly all of the work done exploring this relationship has been in a wound healing 
context with dermal myofibroblasts, or cancer setting with tumor myofibroblasts. Lastly, 
the physiological roles of potential MSC progenitors and their differentiated forms have 
often been overlooked.  The aim of my project was to simultaneously tackle each of the 
three issues above by examining the possible angio-adaptive relationship between 
endothelial cells, and a novel myofibroblast progenitor derived from human skeletal 
muscle.  
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OBJECTIVES 
1. To establish if myofibroblasts differentiated from newly discovered human 
skeletal muscle derived CD90+ progenitors have angio-adaptive properties 
through a paracrine relationship with endothelial cells. 
 
2. To determine if the above angio-adaptive relationship is modified with metabolic 
disturbances such as hyperglycemia – a well established component of a 
diabetogenic model for endothelial cells. 
 
 
 
HYPOTHESIS 
1. Differentiated myofibroblasts will display a stronger pro-angiogenic activity 
compared to their CD90+ progenitor cells. 
 
2. Hyperglycemic differentiation of CD90+ progenitors will negatively modify the 
pro-angiogenic properties of differentiated myofibroblasts. 
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MATERIALS AND METHODS 
Human tissue collection and myofibroblast isolation, culture, differentiation, and 
conditioned media collection were performed by Dr. Grenier’s group at the University of 
Sherbrooke. 
 
Human Tissue 
Healthy human skeletal muscle tissue samples (gracilis and semitendinosus) 
were obtained from patients (34 ± 8 years of age; 54% male and 46% female) 
undergoing anterior cruciate ligament reconstruction surgery. The samples were 
collected following resection surgery. The protocols were approved by the Centre 
Hospitalier de l’Université de Sherbrooke Ethics Committee (#11-122 and #13-164), and 
written consent was obtained from all patients. 
 
CD90+ Progenitor Cell Isolation and Culture 
Carefully dissected skeletal muscle samples were minced and then digested for 
30 min at 37°C with 1 mg/mL of collagenase type I (Sigma) in DMEM containing 10% 
FBS. The tissue slurry was diluted with medium, passed through 70-µm and 40-µm cell 
strainers (Becton Dickenson), and centrifuged at 325g for 6 min at 4°C. Primary human 
cells were seeded in tissue culture plates coated with Mesencult-SF® attachment 
substrate and were expanded as adherent cells in Mesencult-XF® medium (StemCell 
Technologies). After 7 days, an average of 7x105 adherent cells were recovered per 
gram of tissue. The cells were trypsinized at 80% confluence and were centrifuged and 
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resuspended in Mesencult-XF® medium as first passage cells, with fresh medium 
changes every 3-4 days. The cells were sub-cultured at a density of 4x103 cells/cm2. 
 
Fluorescence-Activated Cell Sorting 
First passage cells were detached with the Accutase™ Cell Detachment solution 
(BD Biosciences), centrifuged, and resuspended at ~1x106 cells per ml in cold sorting 
buffer (PBS, 1 mM EDTA, 25 mM HEPES, pH 7.0, 1% FBS). The cells were incubated 
for 20 min on ice, according to the manufacturers’ instructions. During the cell sorting 
experiment, live cells were distinguished from dead cells using LIVE/DEAD® Violet 
Viability/Vitality kits (Invitrogen). Fluorescence was compensated using BD CompBeads 
Set Anti-Mouse Ig, κ (BD Biosciences). The cells were sorted using a BD FACSAria™ 
cell sorter (BD Biosciences) equipped with four lasers and a 100-µm nozzle set at 20 
psi. Sorting gates were defined based on unstained controls. The cells were analyzed 
using FlowJo 7.9 software (Treestar Inc.). A population of unsorted cells was used as a 
control.  
 
Myofibroblast Differentiation  
The cells were seeded at a density of 8 × 103 cells per well in 24-well collagen-
coated (Millipore) plates (4000 cells/cm2) in Mesencult-XF® medium and incubated at 
37 °C in a CO2 incubator until they reached confluence. To stimulate myofibroblastic 
differentiation, CD90+ progenitor cells were incubated in myofibroblast differentiation 
medium (DMEM 2% HS, 1% antibiotics) containing 25 ng/ml TGFβ for 5 days. The 
TGFβ was omitted for the un-stimulated controls. Differentiation media was either 
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normoglycemic (5 mM glucose) or hyperglycemic (25 mM glucose) and were changed 
twice every 3 or 4 days.  
 
Endothelial Cell Culture 
Primary human dermal microvascular endothelial cells were purchased from 
ScienCell Research Laboratories (Cat. 2000, Lot 8219, Carlsbad, CA, U.S.A.). Cells 
were cultured at 37oC and 5% CO2, on T75cm2 coated with 50μg/mL collagen I, from rat 
tail (Gibco, cat. A10438-01, Burlington, ON, Canada) in 0.02 M acetic acid (Sigma-
Aldrich, cat. 320099, Oakville, ON, Canada). Cells were maintained in Endothelial Cell 
Media (ECM, ScienCell, Cat. 1001, Carlsbad, CA, U.S.A.) supplemented with 5% fetal 
bovine serum (ScienCell, Cat No. 0025, Carlsbad, CA, U.S.A.), 1% endothelial cell 
growth supplement (ECGS, ScienCell, Cat. 1052, Carlsbad, CA, U.S.A.), and antibiotic 
solution containing 100 U/mL of penicillin and 100 μg/mL streptomycin (ScienCell, Cat. 
0503, Carlsbad, CA, U.S.A.). 
 
Conditioned Media (secretome) Collection 
CD90+ & Myofibroblast conditioned media: 
Cells were seeded and allowed to grow to 80% confluence. CD90+ cells were 
stimulated with normo- or hyperglycemic differentiation medium for 72 hours. Cells were 
rinsed with PBS (Gibco, Cat. A10438-01, Burlington, ON, Canada), and serum free 
medium with 1% BSA was added. Cells were allowed to incubate for 72 hours before 
the supernatant was collected. The supernatant was centrifuged at 5000g for 5 minutes 
to remove cellular debris, and the conditioned media was collected. 
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HDMEC conditioned media:  
HDMEC were cultured under normo- (5 mM glucose) or hyperglycemic (25 mM 
glucose) conditions for 12 days (3 passages). Cells were then seeded and allowed to 
grow to 70% confluence. Cells were rinsed with PBS (Gibco, cat. A10438-01, 
Burlington, ON, Canada), and serum free endothelial cell medium (ECM) (ScienCell, 
Cat. 1001, Carlsbad, CA, U.S.A.) supplemented with 1% Bovine Serum Albumin (BSA) 
(Sigma-Aldrich, cat. A7906, St. Louis, MO, U.S.A) was added. The cells were allowed to 
incubate for 24 hours before the supernatant was collected. The supernatant was 
centrifuged at 5000g for 5 minutes to remove cellular debris, and the conditioned media 
was collected. 
 
Protein Concentration Determination 
 Determination of total protein concentration was done using the Bicinchoninic 
Acid Assay (BCA). The BCA solution was prepared from Bicinchoninic Acid (Sigma-
Aldrich, cat. B9643, Oakville, ON, Canada) and Copper II Sulphate (Sigma-Aldrich, cat. 
C2284, Oakville, ON, Canada) solutions in a 20:1 ratio, respectively. Samples to be 
analyzed were loaded in triplicate into a 96-well round bottom plate (Sarstedt, cat. 
82.1581, Newton, NC, U.S.A.). Samples were compared to a standard curve, plotted by 
using dilutions of a stock 2 mg/ml solution of Bovine Serum Albumin (Sigma-Aldrich, 
cat. A7906, St. Louis, MO, U.S.A). Plates were incubated at 37°C for 30 minutes and 
the absorbance was read at 562 nm on a plate reader (Wallack Victor3 1420 Multilabel 
Counter, PerkinElmer). 
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Angiogenesis Proteome Profiler Array  
The assay was run according to the manufacturer’s instructions (R&D Systems, 
cat. ARY007, Burlington, ON, Canada). Conditioned media samples were incubated 
with nitrocellulose membranes pre-probed with primary antibodies against 55 positive 
and negative regulators of angiogenesis, with each antibody being spotted in duplicate 
on the membranes. Each membrane was incubated with 300 µg of total proteins from 
conditioned media samples. Conjugated protein spots were visualized by incubating 
each membrane with a cocktail of biotinylated detection antibodies, streptavidin-
horseradish peroxidase, and visualized using Millipore Luminata™ HRP 
Chemiluminesence Detection Reagents (cat. WBLUC0100, WBLUR0100, 
WBLURUF0100, Thermo Scientific, Nepean, ON, Canada). Protein spots were 
quantified using a Kodak Imaging station 4000MM Pro with Carestream software. 
 
Endothelial Cell Migration 
One day prior to the cell migration assay, cells were trypsinized, collected, 
counted, and re-plated. Migratory activity was measured using a Boyden chamber 
assay (Neuro Probe Inc, cat. AP48, Gaithersburg, MD, U.S.A.). A Polycarbonate 
membrane filter with 8μm pores (Neuro Probe, Inc., cat. PFB8, Gaithersburg, MD, 
U.S.A.) was coated with 50μg/mL collagen (Gibco – Life Technologies, cat. A10438-01, 
Burlington, ON, Canada) in 0.02 M acetic acid (Sigma-Aldrich, cat. 320099, Oakville, 
ON, Canada) and allowed to incubate overnight prior to the assay at 4oC.  
Cells were used between passages 5 to 10. Cells were collected and resuspened 
in ECM (ScienCell, cat. 1001, Carlsbad, CA, U.S.A.) supplemented with 1% Fetal 
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Bovine Serum (ScienCell, cat. 0025, Carlsbad, CA, U.S.A.) at a concentration of 440 
cells/μl. Wells of the bottom chamber were loaded with 28 μl of either non-stimulating, 
stimulating, or conditioned media. Stimulating medium consisted of ECM (ScienCell, 
cat. 1001, Carlsbad, CA, U.S.A.) supplemented with 10% Fetal Bovine Serum 
(ScienCell, Cat. 0025) and 5% Endothelial Cell Growth Supplement (ScienCell, cat. 
1052, Carlsbad, CA, U.S.A.), while non-stimulating medium consisted of ECM 
(ScienCell, cat. 1001, Carlsbad, CA, U.S.A.) supplemented with 1% Fetal Bovine Serum 
(ScienCell, cat. 0025, Carlsbad, CA, U.S.A.). These two conditions were used 
respectively as positive and negative controls. Wells of the top chamber were filled with 
50 μl of cell suspension (440 cells/μl). The assembled and filled chamber was placed in 
the incubator at 37oC and 5% CO2, and cells were allowed to migrate for 4.5 hours. 
Following migration, the membrane was incubated in 20 mL cold (4 oC) methanol 
(Caledon Laboratory Chemicals, cat. 6700-1, Georgetown, ON, Canada) for 10 minutes 
at room temperature. The membrane was then washed 3 times with cold (4 oC) double 
distilled water and stained using 2 mL of Giemsa stain (Sigma-Aldrich, cat. GS500, 
Oakville, ON, Canada) diluted in 20 mL double distilled water, and allowed to incubate 
for 30 minutes at room temperature. The membrane was briefly destained in double 
distilled water and mounted on a microscope slide. A damp cotton swab was used to 
carefully scrape the non-migrated cells from the top of the membrane. Cells were 
counted under 40X magnification, with 4 counts performed per well. Counting was 
expressed as cells per field of view.   
 
 
25 
 
Gene Expression 
Primary human microvascular endothelial cells were treated with CD90+ 
progenitor or myofibroblast conditioned media for 16 hours, or grown under normo- and 
hyperglycemic conditions over a 12 days (3 passages). Following stimulation, RNA was 
collected using the Cell-to-cDNA II kit (Ambion - Life Technologies, cat. 1722, 
Burlington, ON, Canada). cDNA samples were analysed by Taqman real-time 
quantitative polymerase chain reaction (qPCR) with an ABI 7500 Fast PCR system 
(Invitrogen – Life Technologies, Burlington, ON, Canada) using qPCR master mix 
(Invitrogen – Life Technologies, cat. 11743, Burlington, ON, Canada) and Taqman 
probes targeted to VEGF-A, TSP-1, and Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT), followed by quantification using comparative ΔΔCT 
analysis to determine relative mRNA expression. HPRT was used as a housekeeping 
gene. 
 
Western Blots 
 Immunoblotting was carried out on protein extracts from human dermal 
microvascular endothelial cells that underwent treatment with conditioned media or 
normo/hyperglycemic culture conditions. Protein was extracted using lysis buffer 
containing mg/mL phenylmethylsulfonyl fluoride, 1 mmol/L Na3VO4, 1 mmol/L NaF 
(Sigma-Aldrich, Oakville, ON, Canada), and 1X protease inhibitors (Complete Mini and 
PhosStop tablets from Roche Diagnostics, Laval, QC, Canada). Twenty micrograms of 
protein per sample, as determined by BCA, was prepared in a loading buffer containing 
2.84 M β-mercaptoethanol, 0.28 M Sodium dodecyl sulfate, 2.69 M sucrose, 14 μM 
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bromophenol blue, and 0.1 M of 0.5 M Tris pH 6.8, before being boiled at 100°C for 6 
minutes.  Samples were loaded into 7.5-15% SDS polyacrylamide gel and separated by 
electrophoresis at 200V, at room temperature (please refer to Appendix A for details). 
Proteins were then transferred on to a 0.45 μm nitrocellulose membrane (Fisher 
Scientific, cat. 45004000, Toronto, ON, Canada) at 4°C for 70-80 minutes (please refer 
to Appendix A), at 100 V, using the wet transfer method.  
After blocking with 5% fat-free milk in tris buffer saline (TBS) containing 0.1% 
tween at room temperature for 45 min, the blots were probed overnight at 4°C with light 
agitation, with primary antibodies against the following proteins: vascular endothelial 
growth factor – A (VEGF-A) (clone VG-1, cat. 05-1117, Millipore, Temecula, CA, 
U.S.A.), thrombospondin-1 (TSP-1) (clone A6.1, cat. MS-421-P0, NeoMarkers – 
Thermo Scientific, Nepean, ON, Canada), phospho-VEGF receptor 2 (Tyr1175) (clone 
DB511, cat. 3770, Cell Signaling, Beverly, MA, U.S.A.), p38 MAPK (cat. 9212, Cell 
Signaling, Beverly, MA, U.S.A.), phospho-p38 (clone D-8, cat. sc-7973, Santa Cruz 
Biotechnologies, CA, U.S.A.), β-actin (clone C4, cat. sc-47778, Santa Cruz 
Biotechnologies, CA, U.S.A.), α/β Tubulin (cat. 2148, Cell Signaling, Beverly, MA, 
U.S.A.). β-actin and α/β-tubulin were detected as loading controls (Please see Appendix 
A for all antibody concentrations). Membranes were then probed for 60 minutes and at 
RT under light agitation with the following appropriate secondary antibodies diluted in 
5% BSA: HRP conjugate Rabbit anti-mouse (cat. p0260, Dako, Mississauga, ON, 
Canada),  or HRP conjugated Mouse anti-rabbit (cat. 7074, Cell Signalling, Pickering, 
ON, Canada).  
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Proteins were visualized using Millipore Luminata™ HRP Chemiluminesence 
Detection Reagents (cat. WBLUC0100, WBLUR0100, WBLURUF0100, Thermo 
Scientific, Nepean, ON, Canada) and the signals were detected using CL-Exposure™ 
Film (Thermo Scientific, Nepean, ON, Canada). Western blot images were digitized, 
and analyzed with Carestream Molecular Imaging software (Carestream Health, 
Rochester, NY, U.S.A.). Protein expression levels were normalized to loading control 
expression levels, and the respective ratios were compared between different groups.  
 
Statistical analysis 
Analyses were performed using Prism5 software (GraphPad). All data are 
presented as means ± S.E.M. T-tests were used to analyze the results of mRNA and 
protein expression for differences between the respective stimulatory conditions.  One-
way ANOVA and two-way ANOVA were used to analyze the results of the Boyden 
chamber migration assays. Differences between the groups were determined using 
Newman Keuls’ post-hoc test. The results were considered to be statistically significant 
when P ≤ 0.05. 
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RESULTS  
Differentiated myofibroblasts express key angioadaptive factors. 
 Before exploring their potential angiogenic relationship with endothelial cells, we 
examined if myofibroblasts (MyoFib) differentiated from skeletal muscle derived CD90+ 
progenitors (CD90+) represented a source of angioadaptive factors. We specifically 
measured VEGF-A and TSP-1 gene expression by Taqman qPCR. While the 
myofibroblasts expressed VEGF-A and TSP-1 mRNA, there were no significant 
differences in expression whether the differentiation took place under normoglycemic or 
hyperglycemic conditions [Figure 4, VEGF: 0.94 ± 0.04 CD90+ vs. 1.11 ± 0.05 MyoFib, 
TSP-1: 1.12 ± 0.06 CD90+ vs. 1.19 ± 0.05].  
 
Myofibroblast conditioned media (secretome) is enriched with pro-angiogenic 
factors compared to CD90+ progenitor cells' secretome, and stimulates human 
dermal microvascular endothelial cell migration. 
 We next wanted to assess the angio-adaptive profile of the secreted proteins 
from CD90+ progenitors and differentiated myofibroblasts. Conditioned media 
(secretome) was collected from CD90+ progenitors and differentiated myofibroblasts, 
and analyzed via a proteome profiler array (See Appendix 4 for full results). 
Myofibroblast conditioned media was characterized by an increased expression of 
several pro-angiogenic factors, including VEGF and angiopoietin-1, when compared to 
the conditioned media from CD90+ progenitor cells. Anti-angiogenic factors such as 
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TSP-1 and TIMP-1 appear to be secreted less in differentiated myofibroblasts [Figure 
5].  
Given the change seen in the angiogenic profile of the secretome following 
differentiation, we looked to examine the possible functional impact of the respective 
secretomes on HDMEC migration through the Boyden Chamber assay. HDMECs 
stimulated with myofibroblast secretome migrated 60% more than cells treated with 
CD90+ progenitor cell secretome, complementing the changes seen in the proteome 
array of the secretomes [Figure 6, 92.3 ± 3.6 % CD90+ vs. 146.8 ± 3.9 % MyoFib, P ≤ 
0.001]. 
 
HDMEC treated with myofibroblast conditioned media expressed increased levels 
of phosho-p38 and VEGF-A, with no change in TSP-1 or phospho-VEGF-R2. 
With the changes seen in HDMEC functionality following treatment with 
conditioned media, we explored the possible changes in HDMEC molecular signalling 
that could be involved. We investigated phospho-p38 expression, as p38 MAP kinase 
activation by VEGF has been shown to mediate endothelial cell migration (Koch & 
Claesson-Welsh, 2012; Rousseau et al., 1997).  HDMECs treated with myofibroblast 
secretome expressed a 73% increased levels of phospho-p38 protein (relative to total 
p38) when compared to HDMECs treated with CD90+ progenitor secretome [Figure 8, 
0.15 ± 0.01 CD90+ vs. 0.26 ± 0.04 Myofib, *, P ≤ 0.05]. We next examined HDMEC 
VEGF-A and TSP-1 mRNA and protein expression to gain a perspective of the 
autocrine angiogenic state of the endothelial cells exposure to the conditioned media. 
HDMEC treated with myofibroblast secretome had a 75% increase in VEGF-A mRNA 
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expression [Figure 7, 1.00 ± 0.03 CD90+ vs. 1.75 ± 0.19 MyoFib, **, P ≤ 0.01], and a 
110% increase in VEGF-A protein expression [Figure 7, 0.62 ± 0.07 CD90+ vs. 1.30 ± 
0.13 MyoFib, *, P ≤ 0.05]. HDMEC thrombospondin-1 mRNA [Figure 7, 1.00 ± 0.09 
CD90+ vs. 1.01 ± 0.04 MyoFib] and protein expression [Figure 7, 0.61 ± 0.03 CD90+ vs. 
0.50 ± 0.03 MyoFib] were unaltered following treatment with CD90+ or Myofib 
conditioned media. The change in protein levels was further represented as a VEGF to 
TSP-1 ratio, which increased by 153% in the HDMECs treated with the myofibroblast 
conditioned media [Figure 7, 1.02 ± 0.17 CD90+ vs. 2.58 ± 0.38 MyoFib, *, P ≤ 0.05]. 
There was no change in phospho-VEGF-R2 protein expression between the two 
treatment conditions [Figure 8, 0.52 ± 0.17 CD90+ vs. 0.77 ± 0.11 MyoFib].   
 
Differentiation of myofibroblasts under hyperglycemic conditions attenuates the 
pro-angiogenic profile of the secretome, and reduces the pro-migratory impact on 
HDMECs. 
 Conditioned media collected from myofibroblasts differentiated under 
hyperglycemic conditions (25 mM glucose) appeared to have an overall decrease in 
pro-angiogenic factors, including angiopoietin-1 and VEGF, with relative little change or 
increase in anti-angiogenic factors [Figure 9].  
Given the changes in the proteome array, we examined if hyperglycemic 
differentiation had an impact on the secretomes’ ability to induce HDMEC migration. 
There was no difference in the ability of progenitor CD90+ secretome to stimulate 
migration following normo- or hyperglycemic exposure [Figure 10, 103.3 ± 2.7% CD90+ 
NG vs. 103.8 ± 1.5 % CD90+ HG]. HDMEC stimulated with conditioned media collected 
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following normoglycemic differentiation migrated 49% more than those stimulated with 
CD90+ progenitor conditioned media, confirming what shown earlier in the results 
above [Figure 10, 103.3 ± 2.7% CD90+ NG vs. 155.1 ± 2.8 % Myofib NG - effect of 
differentiation, †††, P ≤ 0.001]. When the conditioned media was collected following 
hyperglycemic differentiation, treated HDMECs had only a 10% increase in migration 
compared to CD90+ progenitor conditioned media [Figure 10, 103.8 ± 1.5 % CD90+ HG 
vs. 113.0 ± 2.1 % Myofib HG – Effect of differentiation, †, P ≤ 0.05]. Importantly, this 
represents a 27% reduction in migration when comparing the stimulation by conditioned 
media collected following normoglycemic or hyperglycemic differentiation [Figure 10, 
155.1 ± 2.8 % Myofib NG vs. 113.0 ± 2.1 % Myofib HG – Effect of HG, $$$, P ≤ 0.001].  
 
HDMECs treated with myofibroblast secretome collected following hyperglycemic 
differentiation had an increase in VEGF-A mRNA expression, with no change in 
VEGF-A, TSP-1, phospho-38, or phosho-VEGF-R2 protein levels.  
 HDMEC treated with myofibroblast secretome collected following hyperglycemic 
differentiation expressed 61% higher levels of VEGF-A mRNA compared to those 
treated with conditioned media following normoglycemic differentiation [Figure 11, 1.76 
± 0.19 MF NG vs. 2.83 ± 0.16 MF HG, ***, P ≤ 0.001].  However, there was no change 
in VEGF-A protein expression between the two groups. [Figure 11, 1.30 ± 0.13 MF NG 
vs. 1.10 ± 0.09 MF HG]. There were also no significant differences in TSP-1 mRNA 
expression [Figure 11, 1.01 ± 0.04 MF NG vs. 1.03 ± 0.078 MF HG] or protein 
expression [Figure 11, 0.50 ± 0.03 MF NG vs. 0.58 ± 0.04 MF HG]. While there 
appeared to be a trend for a decrease in phospho-p38 (relative to total p38), there was 
32 
 
no significant difference between the HDMECs treated with the different conditioned 
media. [Figure 12, 0.26 ± 0.04 MF NG vs. 0.17 ± 0.04 MF HG].  Lastly, there was no 
significant difference in p-VEGF-R2 expression between the two groups [Figure 12, 0.77 
± 0.11 MF NG vs. 0.91 ± 0.18 MF HG].   
 
HDMEC cultured under hyperglycemia have reduced migratory activity. 
 HDMEC cultured under hyperglycemic (25 mM) conditions over a 12 day period 
(3 passages)  had  a 13 % reduction in basal migration in response to the no-stimulation  
(non-stim) condition [Figure 13, 100.0 ± 0.7 % Non-stim NG vs. 87.4 ± 0.7 % Non-stim 
HG, ***, P ≤ 0.001]. The ability of HDMECs to migrate in response to the stimulatory 
condition was also compromised. Cells under normal glucose and exposed to the 
stimulatory condition (stim) underwent a 82% increase in migration compared to the no 
stimulation group [Figure 13, 100.0 ± 0.7 % Non-stim NG vs. 181.7 ± 0.7 % Stim NG, 
***, P ≤ 0.001], however, HDMECs under high glucose, and exposed to the stimulatory 
condition only had a 65% increase compared to the respective non-stim group. This 
represents a 10% decrease in HDMECs ability to respond to the stimulatory condition 
within each respective glucose condition [Figure 13, 87.5 ± 0.7 % Non-stim HG vs. 
144.2 ± 1.2 % Stim HG, †††, P ≤ 0.001].  
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HDMEC cultured under hyperglycemia have unaltered VEGF-A and TSP-1 protein 
expression, but a decrease in phospho-VEGF-receptor 2 protein levels. 
 Following the changes in HDMEC migration with hyperglycemic conditions, we 
looked to investigate the autocrine angiogenic state of the cells. We again looked at 
VEGF-A and TSP-1 expression. VEGF-A mRNA [Figure 14, 0.45 ± 0.05 NG vs. 0.48 ± 
0.05 HG] and protein [Figure 14, 0.23 ± 0.05 NG vs. 0.21 ± 0.03 HG] expression were 
unaltered following culture under hyperglycemia. Thrombospondin-1 mRNA expression 
was 71% higher in HDMEC cultured under hyperglycemia compared to those under 
normoglycemia [Figure 14, 0.55 ± 0.06 NG vs. 0.94 ± 0.10 HG, *, P ≤ 0.05], however, 
protein levels were unaltered between the two culture conditions [Figure 14, 2.92 ± 0.23 
NG vs. 2.84 ± 0.26 HG]. Given the lack of changes in these two angioadaptive factors, 
we examined the phosphorylation of VEGF receptor-2. Phoshpo-VEGF-R2 protein 
expression was 48% lower in HDMEC cultured under hyperglycemia compared to 
normoglycemia [Figure 14, 0.33 ± 0.04 NG vs. 0.17 ± 0.02 HG, **, P ≤ 0.01]. 
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DISCUSSION  
As detailed in the introduction, too little attention has been given to potential role 
supporting cells types could play within skeletal muscle angio-adaption. Concurrently, in 
the investigation of mesenchymal stem cells, the focus has been on the characterization 
of cell types, while the physiological roles of MSC progenitor cells have often been 
overlooked (Murray et al., 2014). We looked to address both of these issues with our 
investigation of the possible angio-adaptive relationship between newly identified 
human skeletal muscle myofibroblast progenitor cells and endothelial cells. 
 We have shown that myofibroblasts acquire a proangiogenic profile when 
differentiated form their skeletal muscle derived CD90+ progenitor cells. This is in 
accordance with other publications suggesting a proangiogenic role for myofibroblasts 
derived from other tissues (Daigle et al., 2013; Mayrand et al., 2012; Vong & Kalluri, 
2011). It is worth being highlighted the good correspondence between results obtained 
at the molecular level for the angio-adaptive proteome profiling and those examining 
aspects of cell functionality such as migration. Although only qualitative, the proteome 
array provided us with an interesting overview of the general angio-adaptive profile of 
secreted proteins from the differentiated myofibroblasts compared to their progenitors. 
In particular, it suggested a general increase in several well-established pro-angiogenic 
factors, and either a decrease or the maintenance of anti-angiogenic molecules when 
comparing the secretome from the CD90+ progenitors to that of the differentiated 
myofibroblasts. These results from the molecular profiling were in line with the functional 
analysis of primary endothelial cell migration. Cell migration was indeed significantly 
increased in response to stimulation with the myofibroblast secretome compared to 
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stimulation with CD90+ progenitor secretome. Considering how endothelial cell 
migration is a fundamental aspect of the angiogenic process, these results strongly 
support the hypothesis of a proangiogenic relationship between CD90+-differentiated 
myofibroblasts and primary endothelial cells.  
Moreover, HDMEC express more proangiogenic VEGF-A when treated with 
myofibroblast secretome compared to CD90+ secretome, while HDMEC TSP-1 
expression remains unaffected. This was shown to be true at both the mRNA and 
protein level. These results provide an overall view of the angio-adaptive state of the 
endothelial cell itself. The shift in the direction of the pro-angiogenic side of the balance 
is further illustrated by the significant increase in the VEGF to TSP-1 ratio, a measure 
that has been previously shown to correlate well with muscle angio-adaptive patterns 
(Roudier et al., 2010).  While it is unclear what the specific roles of endothelial cell 
produced endogenous angio-adaptive factors are during angio-adaptation, autocrine 
VEGF-A signalling has been shown to be required for vascular homeostasis (Lee et al., 
2007).  
We further investigated endothelial signaling pathways the myofibroblast 
conditioned media could be impacting to promote changes seen in cell migration. The 
expression of  phospho-VEGF receptor-2 and phospho-p38 were prime candidates 
given the central role they play in endothelial cell migration signalling following VEGF 
stimulation (Koch & Claesson-Welsh, 2012; Lamalice et al., 2007). A significant 
increase was seen in phospho-p38 expression in the HDMECs treated with the 
myofibroblast secretome. This was consistent with the changes seen in endothelial cell 
migration, and confirmed that the signalling may be occurring through VEGF-Receptor 
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activation and subsequent p38 MAPK signalling. However, there was no change in p-
VEGF-R2 expression in the same cells. Although there was trend for an increase, the 
16 hour treatment with conditioned media may have been too long of a time point to 
capture changes in the phosphorylation of the receptor, while changes in p38 
phosphorylation may have persisted.  
We have also shown that the pro-angiogenic profile of the differentiated 
myofibroblasts was negatively altered when differentiation occurred under 
hyperglycemic conditions. We chose to examine the impact of hyperglycemic stress on 
the myofibroblasts as it considered the hallmark of type 2 diabetes (Bakker et al., 2009; 
Popov, 2010). While it is important to recognize that type 2 diabetes presents a number 
of other detrimental complications such as dyslipidemia and hyperinsulinemia, 
hyperglycemia served as a useful and widely used point of departure to examine the 
myofibroblast–endothelial cell relationship under pathological conditions. It has been 
shown that the differentiation of myofibroblasts appears to be altered under 
diabetogenic conditions (Fowlkes et al., 2013). However, this study utilized cardiac 
myofibroblasts, and focused on the pro-fibrotic consequences rather than angio-
adaptive aspects.  
The qualitative analysis of the proteome profiler suggested that the 
myofibroblasts differentiated under hyperglycemia presented a decreased release of 
pro-angiogenic factors in their secretome compared to cells differentiated under 
normoglycemic conditions. These results were quantitatively supported by the results 
from the cell migration assay, as HDMECs stimulated with secretome from 
myofibroblasts differentiated under hyperglycemic conditions migrated significantly less 
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than those stimulated with secretome from differentiation under nornoglycemia. 
Intriguingly, the decreased migration in response to hyperglycemia was not associated 
with a concomitant decrease in VEGF-A, nor with an increase in TSP-1, at both the 
mRNA and protein level. In fact, VEGF-A mRNA expression was even significantly 
higher in HDMECs stimulated with myofibroblast secretome collected following 
hyperglycemic differentiation compared to normoglycemic differentiation, with no 
change at the protein level. This may suggest that other important angio-adaptive 
factors could be impacting the migratory activity of the endothelial cells. Moreover, given 
that the changes in VEGF-A mRNA are not seen at the protein level, there is a 
possibility of myofibroblasts differentiated under hyperglycemic conditions releasing 
factors that are impacting VEGF translation.  Interestingly, there was not a decrease in 
phospho-p38 expression in the HDMECs treated with the conditioned media collected 
from hyperglycemic differentiation, despite the attenuation of migration observed in the 
Boyden chamber assay. This presents the possibility that other anti-angiogenic factors 
are interacting with the endothelial cells through mechanisms outside of the VEGF-R2 
and p38 MAPK migration pathway.   
 We next looked at the impact of the same hyperglycemic conditions on the 
endothelial cells themselves. It is important to consider that if the progenitors or 
myofibroblasts exist in pathological conditions such as hyperglycemia, they will not be 
isolated. Rather, the endothelial cells themselves will be subjected to the same 
conditions. In normal physiological conditions, endothelial cells are exposed to blood 
glucose levels in the range of ~3.6-5.8 mM, and  cells exposed to glucose levels greater 
than 10 mM, in vitro or in vivo as in diabetes mellitus, are considered be in a high 
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glucose condition (Popov, 2010). Type-2 diabetes is accompanied by a multitude of 
complications that negatively impact the integrity of the microvasculature and 
angiogenic activity (Beckman et al., 2002; Martin et al., 2003). High glucose levels 
disrupt endothelial cell homeostasis, leading to endothelial dysfunction and changes in 
both the macrovasculature and capillaries of the microvasculature (Popov, 2010). In 
diabetes, angiogenic responses are enhanced in some tissues (retina and kidney), 
while they are impaired in other tissues, leading to defective wound healing, peripheral 
circulation, and coronary circulation (Moriya & Ferrara, 2014).  We chose to treat our 
HDMECs with 25mM glucose, as 20 mM to 30 mM glucose conditions have been widely 
used with endothelial cells to replicate hyperglycemia in culture (Gadad, Matthews, & 
Knott, 2013; Manna & Jain, 2014; Morigi et al., 1998; Popov, 2010; Syeda et al., 2012; 
Yang et al., 2008). 
Hyperglycemic treatment had a dual impact on HDMEC migration, as it reduced 
basal migration under the no-stimulation condition, as well as the ability of the HDMECs 
to respond under the stimulatory condition. Interestingly, studies have pointed out both  
pro- and anti-migratory effects of hyperglycemic endothelial cells treatment (Huang et 
al., 2015; Wang, Yang, & Dong, 2013; Warren, Ziyad, Briot, Der, & Iruela-Arispe, 2014; 
Yu et al., 2006; Yuan et al., 2012). However, these works have mostly utilized Human 
Retinal Microvascular Endothelial Cells (HRMECs) or Human Umbilical Microvascular 
Endothelial Cells (HUVECs) with exposure to diabetogenic like conditions of high 
glucose over a relatively short 24 to 48 hour period. Few studies have specifically 
assessed HDMEC migration under following high glucose treatment. Gadad et al. 
reported a decrease in HDMEC migration analysed through wound healing assays 
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following 48 hours of high glucose treatment, while Syeda et al. have shown a decrease 
in HDMEC migration following 3-4 day exposure to high glucose (Gadad et al., 2013; 
Syeda et al., 2012). Our work looked to employ a “chronic” treatment of the HDMECs 
over 12 days, and 3 passages before assessing their migration.  
We next looked to examine what intracellular changes the hyperglycemic 
exposure could be exerting on the endothelial cells that lead to the decreases in 
migration. We again measured VEGF-A and TSP-1 expression to gain an 
understanding of the autocrine angio-adaptive state of the cell. While there was an 
increase in TSP-1 mRNA expression, there was no change in HDMEC VEGF-A or TSP-
1 protein levels, suggesting that these factors were not responsible for the changes 
seen in migration. With no change on the endogenous factor secretion, we chose to 
focus on the expression of p-VEGF-R2. There have been mixed reports regarding 
differences in p-VEGF-R2 expression levels in diabetic vs. non-diabetic individuals 
(Uchida & Haas, 2009). When we investigated p-VEGF-R2 in our HDMECs exposed to 
hyperglycemia, we found a 48% reduction in protein phosphorylation levels compared to 
cells under normoglycemic conditions. It has been suggested that excessive reactive 
oxygen species (ROS) produced by hyperglycemia promote activation of a 
noncanonical VEGF-R2 signalling pathway leading to increased endothelial cell VEGF-
R2 internalization and degradation. As a result, traditional canonical ligand-dependent 
VEGF-R2 signalling is inhibited due to decreased availability of cell-surface VEGF-R2 
(Moriya & Ferrara, 2014; Warren et al., 2014). Warren et al exposed HUVECs to high 
glucose for a minimum of 5 days, and found through wound healing assays that 
HUVECs cultured under high glucose migrated at a slower rate than cells under normal 
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glucose, under both basal conditions and in response to VEGF. These cells also had a 
4 fold decrease in p-VEGF-R2 expression in response to VEGF stimulation, without 
changes in total VEGF-R2 protein. Cell surface biotinylation assays revealed HUVECs 
under high glucose had a decrease in surface abundance of VEGF-R2. They went on to 
show these HUVECs under high glucose exhibited increased ROS production (Warren 
et al., 2014). Interestingly, low concentrations of ROS can contribute to activating 
canonical (pro-angiogenic) signalling of VEGF-R2 under physiological conditions 
(Moriya & Ferrara, 2014). This could explain why in some cases, endothelial cells 
treated with high glucose have been shown to have increased migratory activity, as the 
exposure to the high glucose levels may not have been long enough to induce 
substantial ROS production.   
It is enticing to hypothesize that increased ROS production is occurring in our 
HDMECs exposed to high glucose, leading to the decrease in p-VEGF-R2 expression, 
and subsequent loss of migratory ability.  These results served as the first step in 
examining the myofibroblast relationship from the perspective of the endothelial cell. 
Decreased migration and reduced p-VEGF-R2 expression, possibly caused by 
increased ROS production, could also be indicative of changes in endothelial cell factor 
secretion.  
Reactive oxygen species production in diabetic individuals is accompanied by 
increased production of Endothelin-1 by the dysfunctional endothelium (Creager & 
Libby, 2014; W. T. Wong, Wong, Tian, & Huang, 2010). In this context, Endothelin-1 is 
considered for its role as a vasoconstrictor and stimulator of vascular smooth muscle 
cell growth in the development of atherogenesis (Creager & Libby, 2014). Considering 
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that Endothelin-1 is a known stimulator of myofibroblast differentiation, this provides 
interesting avenues to explore in future works. Changes in the profile of secreted factors 
from the endothelial cells could significantly affect their relationship with the 
myofibroblast or their CD90+ progenitors. 
Figure 3. Summary of potential paracrine relationship between CD90+ progenitors, 
myofibroblasts, and endothelial cells, and how the presented relationship may be 
impacted by a pathological insult such as hyperglycemia.  
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A broad summary of our findings is illustrated in Figure 3. Through our results, it 
appears CD90+ skeletal muscle derived progenitors acquire a pro-angiogenic profile 
when differentiated into myofibroblasts.   However, this pro-angiogenic profile is 
impaired when CD90+ progenitors are differentiated under hyperglycemia. 
Concurrently, hyperglycemia negatively impacts HDMVECs basal migration, and ability 
to respond to pro-migratory stimuli. Therefore, hyperglycemia may have a twofold 
impact in this potential paracrine relationship, as it impairs the ability of myofibroblasts 
to generate pro-angiogenic effectors, while at the same time impairing the ability of the 
endothelial cells to respond to those same factors.  
 
. 
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LIMITATIONS & FUTURE EXPERIMENTS 
 One of the major limitations of this study is that our human endothelial cells were 
from dermal origin, while our CD90+ progenitors were isolated from human skeletal 
muscle. Unfortunately, when beginning the project, we did not have access to human 
skeletal muscle endothelial cells. The popular choices in the literature for in-vitro 
primary human endothelial cell work are currently HUVECs, HDMECs, or human 
adipose microvascular endothelial cells (HAMECs). We felt that HDMECs were the 
most suitable choice to analyse the paracrine relationship between the cells, given the 
roles myofibroblasts play in dermal wound healing.   
 Dr. Grenier has since developed a method to isolate endothelial cells from 
human skeletal muscle. It would be interesting to perform the same experiments in this 
study with CD90+ progenitor cells and endothelial cells isolated from the same human 
skeletal muscle. Another interesting avenue would involve isolating endothelial cells or 
CD90+ progenitors from healthy patients and diabetic patients, and examining the 
paracrine relationship if the cells maintain their pathological phenotype in vitro.  
Other future experiments involve exploring this relationship from the perspective 
of the endothelial cell and the impact it could have on progenitor cell differentiation, or 
myofibroblast survival and functionality. This would involve collecting conditioned media 
from endothelial cells cultured under normal and high glucose conditions, and treating 
progenitor cells and differentiated myofibroblasts, while monitoring changes in α-smooth 
muscle actin, collagen production, and contractility. If changes are seen in progenitor or 
differentiated myofibroblasts, the conditioned media itself could be analyzed for pro-
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differentiation factors such as endothelin-1, sphingosine-1-phosphate, or TGF-β.  These 
experiments would help “complete the loop” by establishing the reciprocal paracrine 
relationship from the perspective of both cell types.  
Further work could be done to examine the possible bio-physical relationship 
between the cell types by utilizing co-culture techniques. The viability and functionality 
of both cell types could be monitored with by co-culturing the cells with different 
concentrations in respect to one another. Tube formation assays using both cell types 
concurrently could provide valuable information about the functional impact of the 
physical relationship on both cell types.  
Lastly, more work could be done to establish the anatomical presence of the 
progenitors, and how it may change once differentiation takes place. Histological work 
in samples from healthy or diabetic individuals could provide useful information to the 
quantity and location of these progenitors or differentiated myofibroblasts. Being able to 
show that the cells are in the proximity of the microvasculature strengthens the results 
examining their potential paracrine relationship.   
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CONCLUSION  
Through this project, we have been able to provide preliminary evidence aimed 
at answering the broad questions we had identified regarding the physiological roles of 
mesenchymal stem cells, and myofibroblasts in angiogenesis. We have focused on the 
possible role of a supporting cell type other then the muscle tissue itself in skeletal 
muscle angiogenesis. Concurrently, we have expanded on the characterization of a 
newly identified skeletal muscle myofibroblast progenitor by examining its potential 
physiological role.   
We have shown that myofibroblasts acquire a pro-angiogenic profile following 
differentiation from CD90+ progenitor cells derived from human skeletal muscle. This 
was demonstrated with good correspondence between changes seen at the molecular 
level, and changes in cell functionality. Interestingly, this pro-angiogenic profile seems 
to be negatively altered when differentiation takes place under hyperglycemic 
conditions. Through these results, we believe we have established a good basis for the 
relationship between the CD90+ progenitor, myofibroblast, and endothelial cells.  
These results focus on the relationship from the perspective of the myofibroblast, 
and its actions on the endothelial cell. Through future experiments, we would like to 
explore the relationships from the perspective of the endothelial cell. If changes in 
myofibroblast differentiation are seen through altered secreted factors from endothelial 
cells under hyperglycemia, then we can begin to suggest that there is in fact a 
reciprocal relationship that is negatively impacted in a metabolically disturbed state.  
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Myofibroblast VEGF-A and TSP-1 mRNA expression. CD90+ progenitor 
cells were differentiated into myofibroblasts under normoglycemic (5 mM glucose) or 
hyperglycemic (25 mM glucose) conditions. VEGF-A and TSP-1 mRNA levels were 
measured by Tapman qPCR and relative expression quantified relative to the 
housekeeping gene HPRT. Data are shown as means ± SEM with n = 4 groups per 
condition. 
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Figure 5. Myofibroblast secretome is enriched in pro-angiogenic factors. The 
expression level of 55 proteins involved in regulating angio-adaption was measured in 
CD90+ progenitor and differentiated myofibroblast secretomes using an angiogenesis 
proteome profiler array. (A) Representative proteome profiler membranes of secreted 
proteins from CD90+ precursors or differentiated myofibroblasts. (B) Relative changes 
in established pro-angiogenic and anti-angiogenic factors.  
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Figure 6. Myofibroblast secretome stimulates HDMEC migration. Representative 
Boyden Chamber migration assay from primary endothelial cells stimulated with CD90+ 
progenitor or differentiated myofibroblast secretome. (A) Representative photos of the 
migration of endothelial cells in the Boyden Chamber, in vitro model. Cells are allowed 
to migrate for 4.5 hours through a nitrocellulose membrane with 8 micron pores, and are 
then stained with Giemsa. (B) Quantification of the migration shown in (A). Values 
shown are averages obtained with SEM from 3 independent experiments, each 
comprising n = 6 wells per condition migration. Four counts per well were completed. 
10% serum, 5% ECGS served as positive control. Significantly different within each 
condition, ***, P≤0.001. 
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Figure 7. VEGF-A and TSP-1 mRNA and protein expression in HDMEC treated 
with CD90+ progenitor or myofibroblast secretome. HDMECs were stimulated with 
secretome from CD90+ and differentiated myofibroblasts for 16 hours. VEGF-A and 
TSP-1 mRNA levels were measured using Taqman qPCR and relative expression 
quantified relative to the housekeeping gene HPRT. Respective protein levels were 
measured using western blot, and further analysed as a VEGF to TSP-1 ratio. Data are 
shown as mean ± SEM from n = 3 samples from each differentiation condition. 
Significantly different from CD90+: ** P≤0.01; * P≤0.05.   
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Figure 8. p38, phospho-p38, and phospho-VEGF-R2 protein expression in 
HDMECs treated with CD90+ progenitor or myofibroblast secretome. HDMECs 
were stimulated with secretome from CD90+ and differentiated myofibroblasts for 16 
hours. p-VEGF-R2, p38, and p-p38 protein levels were measured using western blot. 
Data are shown as mean ± SEM from n = 3 samples from each differentiation condition. 
Significantly different from CD90+: *, P≤0.05. 
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Figure 9. Hyperglycemic differentiation inhibits the pro-angiogenic profile of 
myofibroblast secretome. The expression level of 55 proteins involved in regulating 
angio-adaption was measured in differentiated myofibroblast secretomes using an 
angiogenesis proteome profiler array. (A) Representative proteome profiler membranes 
of secreted proteins from myofibroblasts differentiated under normo- or hyperglycemia. 
(B) Relative changes in established pro-angiogenic and anti-angiogenic factors. 
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Figure 10. Myofibroblast secretome obtained following hyperglycemic 
differentiation reduced HDMEC migration. (A) Representative Boyden Chamber 
migration assays from primary endothelial cells stimulated with CD90+ and 
myofibroblast secretomes obtained under normoglycemic (NG) or hyperglycemic (HG) 
differentiation. Cells are allowed to migrate for 4.5 hours through a nitrocellulose 
membrane with 8 micron pores, and are then stained with Giemsa. 10% serum, 5% 
ECGS served as positive control. (B) Quantification of the migration shown in (A). 
Values shown are averages obtained with SEM from 3 independent experiments, each 
comprising n = 6 wells per condition migration. Four counts per well were completed.  
Significantly different from no stimulation: ***, P≤0.001; *, P≤0.05 (1W-ANOVA). 
2W-ANOVA analysis of the effect of differentiation and HG on the ability of the 
secretome to stimulate migration: Effect of differentiation, †††, P≤0.001; †, P≤0.05. 
Effect of HG, $$$ P≤0.001. 
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Figure 11. VEGF-A and TSP-1 mRNA and protein expression in HDMECs treated 
with secretome from myofibroblasts differentiated under normo- or 
hyperglycemia. HDMECs were stimulated for 16 hours with secretome from 
myofibroblasts differentiated under normo- or hyperglycemic conditions. VEGF-A and 
TSP-1 mRNA levels were measured using Taqman qPCR, and relative expression 
quantified relative to the housekeeping gene HPRT. Respective protein levels were 
measured using western blot. Data are shown as mean ± SEM from n = 3 samples from 
each differentiation condition. Significantly different from MyoFib NG: *** P≤0.001. 
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Figure 12. p38, phospho-p38, and p-VEGF-R2 protein expression in HDMEC 
treated with secretome from myofibroblasts differentiated under normo- or 
hyperglycemia. HDMECs were stimulated for 16 hours with secretome from 
myofibroblasts differentiated under normo- or hyperglycemic conditions. P-VEGF-R2, 
p38, and p-p38 protein levels were measured using western blot. Data are shown as 
mean ± SEM from n = 3 samples from each differentiation condition. 
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Figure 13. Inhibitory effect of chronic high glucose on the migratory activity of 
primary human microvascular endothelial cells. Primary human microvascular 
endothelial cells were grown under normoglycemic (5mM) or hyperglycemic (25mM) 
conditions over 12 days (3 passages, p5 to p8). (A) Representative photos of the 
migration of endothelial cells in the Boyden Chamber, in vitro model. Cells are allowed 
to migrate for 4.5 hours through a nitrocellulose membrane with 8 micron pores, and are 
then stained with Giemsa. (B) Quantification of the migration shown in (A). Values 
shown are averages obtained with SEM from 3 independent experiments, each 
comprising n = 6 wells per condition migration. Four counts per well were completed. 
Significantly different from no stimulation, normal glucose, ***, P≤0.001. Significantly 
different from no stimulation, high glucose ###, P≤0.001. Significantly different from 
normal glucose, stimulation, †††, P≤0.001. 
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Figure 14. VEGF-A, TSP-1 mRNA and VEGF-A, TSP-1, and p-VEGF-R2 protein 
expression in HDMEC cultured under normo- or hyperglycemia. HDMECs were 
cultured for 12 days (3 passages) under normoglycemic (5 mM glucose) or 
hyperglycemic (25 mM glucose) conditions. VEGF-A and TSP-1 mRNA levels were 
measured using Taqman qPCR, and relative expression quantified relative to the 
housekeeping gene HPRT. VEGF-A, TSP-1, and p-VEGF-R2 protein levels were 
measured using western blot. Data are shown as mean ± SEM from n = 4 samples from 
each differentiation condition. Significantly different from Normal Glucose: *, P≤0.05, ** 
P≤0.01. 
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APPENDICES 
APPENDIX A – Western Blotting 
Percentage of SDS gel, electrophoresis time, transfer time, and antibody concentration 
used during western blotting. 
Protein 
Target 
Percentage 
Acrylamide Gel 
Electrophoresis 
Time (minutes) 
Electrotransfer 
Time (minutes) 
Primary 
antibody conc. 
p38 10 70 70 1:1000 
p-p38 10 70 70 1:500 
p-VEGF-R2 7.5 55 75 1:1000 
TSP-1 7.5 60 70 1:200 
VEGF-A 15 65 70 1:500 
 
Loading Controls 
Protein Target Primary Antibody Concentration 
α/β Tubulin 1:1000 
β-Actin 1:4000 
 
Western Blot Solutions 
 
 
Separating Buffer 
1.5 M Tris, pH 8.8 + 0.4% SDS 
Total Volume Molecular 
Weight 
Final Conc. 50 ml 100 ml 
Tris Base 121.14 g/mol 1.5 M 9.09g  18.18g 
20% SDS  288.38 g/mol 0.4% 1 ml 2 ml 
H2O N/A N/A Up to final volume 
pH pH 8.8  
NOTE: STORE AT 4°C 
Stacking Buffer 
0.5 M Tris, pH 6.8 + 0.4% SDS 
Total Volume Molecular 
Weight 
Final Conc. 50 ml 100 ml 
Tris Base 121.14 g/mol 0.5 M 3.03g  6.06g 
20% SDS  288.38 g/mol 0.4% 1 ml 2 ml 
H2O N/A N/A Up to final volume 
pH pH 6.8  
NOTE: STORE AT 4°C 
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5X Running/Electrophoresis Buffer 
Total Volume Molecular 
Weight 
Final Conc. 
(5X) 
Final Conc. 
(1X) 
1L (5X) 
Tris 121.14 g/mol 125 mM 25 mM  15.15g 
Glycine 75.07 g/mol 960 mM 192 mM 72.00g 
SDS 288.38 g/mol 17.34 mM 3.47 mM 5.00g 
H2O N/A N/A Up to Final Volume 
NOTE: STORE AT R.T. 
 
5X Transfer Buffer W/O Methanol 
Total Volume Molecular 
Weight 
Final Conc. 
(5X) 
Final Conc. 
(1X) 
1L (5X) 
Tris 121.14 g/mol 125 mM 25 mM  15.15g 
Glycine 75.07 g/mol 960 mM 192 mM 72.00g 
H2O N/A N/A Up to Final Volume 
NOTE: STORE AT R.T. 
1X TRANSFER BUFFER SHOULD HAVE 20% METHANOL WHEN COMPLETE 
 
10x Tris Solution 
Total Volume Molecular 
Weight 
Final Conc.  500 ml 1L  
Tris 121.14 g/mol 500 mM 30.275g  60.55g  
pH pH 7.6 
H2O N/A N/A Up to Final Volume 
NOTE: STORE AT R.T. 
 
Denaturing Blue Buffer 
Compound Molecular Weight 
(g/mol) 
Final 
Concentration 
For 10 ml final 
volume 
Sucrose 342.30 2.69 mM 0.92 g 
SDS 288.38 0.28 M 0.80 g 
Beta-
Mercaptoethanol 
78.13 2.84 M  2 mL 
Bromophenol Blue 691.94 14 μM 10 mg 
0.5 M Tris pH 6.8 N/A N/A 2 mL 
Water N/A N/A Up to final volume 
Stored at -20°C 
 
5% / 5% BSA in 0.1% TTBS 
Milk/BSA 5% of final volume in weight (grams) 
0.1% TTBS Up to final volume  
Stored at 4°C 
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APPENDIX B 
DMEM vs. RPMI – Myofibroblast differentiation media 
Myofibroblast ability to stimulate HDMEC migration is affected by the type 
differentiation media utilized. Using Roswell Park Memorial Institute (RPMI) medium, 
there is a 64% increase in HDMEC migration following stimulation with myofibroblast 
conditioned media compared to CD90+ progenitor conditioned media. However, when 
using Dulbecco’s Modified Eagles Medium (DMEM), there is no change in the ability of 
the conditioned media to stimulate HDMEC migration [Figure A1]. Therefore, the media 
itself appears to have significant impact on the secreted factors from the differentiated 
myofibroblast. This poses questions to be answered in future experiments, specifically, 
identifying which specific factors could be responsible for the changes in myofibroblast 
secretion. Ultimately this represents one of the limits with in vitro cell work, as deciding 
which medium is a better representation of in-vivo conditions is a factor to be taken into 
consideration.  
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Figure A1. Myofibroblast secretome obtained following differentiation using 
DMEM does not stimulate HDMEC migration. Quantification of Boyden Chamber 
migration assays from primary human dermal endothelial cells stimulated with CD90+ 
and myofibroblast secretome obtained under differentiation and conditioning with 
DMEM or RPMI. Values shown are averages obtained with SEM from 3 independent 
experiments, each comprising n = 4 wells per condition migration. Four counts per well 
were completed. Significantly different from no stimulation, ***, P≤0.001. Significantly 
different from CD90+, ###, P≤0.001.  
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APPENDIX C 
Side projects and contributions to the lab outside of my thesis project. 
 
Calibration and validation of the Boyden Chamber migration assay.  
 Prior to my arrival in the lab, the Boyden Chamber migration assay was not a 
routinely used experiment. Therefore, when we acquired the assay, my first task 
involved the calibration and validation of the assay with our dermal and adipose 
microvascular endothelial cells. Calibrating the assay involved the adjustment of 
variables including pore size selection, cell suspension concentration, positive control 
selection, and ideal migration time. The size of the pore in the nitrocellulose membrane 
must be matched to the specific cell type being analysed. A pore that is too large will 
allow any cell with a basal migratory activity to move easily through the membrane, and 
differences in migration will not be readily detectable. An appropriate cell suspension 
density to be loaded into the upper chamber of each well also had to be established. A 
cell density of 440 cells/μl allowed for an appropriate migration under various conditions. 
Most importantly, consistent and reproducible positive control conditions had to be 
established. This was done by using ECM with increasing amounts of fetal bovine 
serum and endothelial cell growth supplement. An ideal solution was found by using 
ECM supplemented with 10% FBS, and 5% ECGS, which consistently provided an 80 – 
100 % increase in cell migration, while ECM with 1% serum served as the no 
stimulation condition.  
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Assessing Mdm2 phosphorylation on Serine 166 as a key regulator of Human 
Dermal Microvascular Endothelial Cells 
 My first project involved utilising the Boyden Chamber assay to examine the role 
of Mdm2 signalling in cell migration. Prior in vivo and in vitro work from the lab had 
identified Mdm2 as a novel regulator of angiogenesis (Roudier et al., 2013; Roudier, 
Forn, Perry, & Birot, 2012). This previous work in the lab examined this relationship 
form a molecular pathway perspective, measuring changes in pro- and anti-angiogenic 
factors, and downstream signalling changes. The aim of my experiments was to 
examine this relationship from an in vitro cell functionality perspective.  
Primary human microvascular endothelial cells were infected with lentivirus 
encoding Mdm2 (Mdm2 Wild-type) or a mimetic of the phosphor-activated form, through 
phosphorylation of serine residue 166 (p-Ser166-Phospho-mimetic Mdm2). Both WT-
Mdm2 and S166D-Mdm2 showed increased protein expression levels of Mdm2 vs. non-
infected HDMEC (281% and 191%, respectively) (Aiken & Roudier, manuscript in 
preparation). The migratory activity of HDMEC was evaluated in the Boyden chamber 
assay [Figure A2]. Over-expression of WT-Mdm2 did not affect basal HDMEC migration 
[Figure A2, B, Non-infected HDMEC: 100.0 ± 2.3 vs. WT-Mdm2: 95.0 ± 3.4, P>0.05]. In 
contrast, over-expression of S166D-Mdm2 significantly enhanced the basal migration 
level by 38% [Figure A2, B, Non-infected HDMEC: 100.0 ± 2.3 vs. S166D-Mdm2: 
138.0% ± 8.4, P≤0.001]. Stimulation with 10% FBS and 5% ECGS enhanced migration 
in all cell lines, respectively by 95% (±8.76) for Non-infected HDMEC, 116% (±4.76) in 
WT-Mdm2, and 275% (±4.17) for S166D-Mdm2 compared to each corresponding non-
stimulated condition [Figure A2, B, P≤0.001]. The percentage of HDMEC migrating 
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under FBS/ECGS stimulation was significantly higher in the S166D-Mdm2 when 
compared to both stimulated Non-infected and WT-Mdm2 cells [Figure A2, B, P≤0.001). 
This suggests that Mdm2 phosphorylation on serine 166 is important for basal and 
stimulated primary microvascular endothelial cell migration. 
 
Montpellier – Skeletal Muscle and Adipose Tissue Capillarization, and VEGF-
A/TSP-1 mRNA expression.  
 My other main contribution to the lab outside of my thesis was through an 
ongoing collaborative project with the Université of Montpellier. Skeletal muscle (vastus 
lateralis) and adipose tissue samples were collected and sectioned from 31 post-
menopusal women. RNA extract was also collected from the same tissues. Insulin 
status was defined using the homeostatic model assessment, HOMA. Ten women were 
healthy and served as controls (BMI<25 Kg/m2, HOMA<3), while 12 were obese and 
insulin sensitive (BMI>30 Kg/m2, HOMA<3), and 9 were obsess and insulin resistant 
(BMI>30 Kg/m2, HOMA>3).  
 Previous work in the lab had examined the capillary to fiber ratio, the capillary 
density, and the adipocyte cross sectional area in a number of the sectioned adipose 
tissue samples. This was accomplished through immunohistochemical staining of 
capillaries by targeting CD31. My role in the project was to complete the 
immunohistochemical staining of additional adipose samples, and to begin the staining 
of muscle tissue samples, while also completing qPCR measurements of angio-
adaptive factors in the RNA extracts from the same patients.  
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 There were no significant differences in muscle tissue capillary density [Figure 
A3, 346.1 ± 15.6 cap/mm2 Ctrl vs. 295 ± 14.7 cap/mm2 Ob-IS vs. 315.3 ± 30.1 cap/mm2 
Ob-IR] or fiber cross sectional area [Figure A3, 3991 ± 229 μm2  Ctrl vs. 4145 ± 296  
μm2 Ob-IS vs. 3480 ± 549 μm2 Ob-IR] between the groups. However, capillary to fiber 
ratio was 11% lower in obese insulin sensitive subjects [Figure A3, 1.36 ± 0.05 C/F Ctrl 
vs. 1.22 ± 0.04 C/F Ob-IS,*, P≤0.05] and 27% lower in obese insulin resistant subjects 
[Figure A3, 1.36 ± 0.05 C/F Ctrl vs. 0.99 ± 0.03 C/F Ob-IR, ***, P≤0.001] compared to 
healthy controls. When focusing on the two obese groups alone, there is an 18% 
decrease in capillary to fiber ratio between insulin sensitive and insulin resistant 
subjects [Figure A3, 1.22 ± 0.04 C/F Ob-IS vs. 0.99 ± 0.03 C/F Ob-IR, †††, P≤0.001].   
There was no significant change in VEGF-A and TSP-1 mRNA expression 
between the groups in either the muscle or adipose tissue samples [Figure A4].  
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Figure A2. The effect of Mdm2 phosphorylation on serine 166, as a regulator of 
endothelial cell migration. (A) Representative Boyden Chamber migration assay from 
primary endothelial cells infected with lentivirus encoding Mdm2 (Mdm2 Wild-type) or a 
mimetic of the phosphor-activated form, through phosphorylation of serine residue 166 
(p-Ser166-Phospho-mimetic Mdm2). Cells were allowed to migrate for 4.5 hours 
through a nitrocellulose membrane with 8 micron pores, and are then stained with 
Giemsa. (B) Quantification from 2 independent experiments, each compromising n = 6 
per condition migration. Four counts were completed per well. Un-supplemented ECM 
served as “no stimulation” condition, while ECM supplemented with 10% serum, 5% 
ECGS served as “stimulation” condition.   
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Figure A3. Effect of obesity and insulin resistance on human skeletal muscle 
capillarization. (A) Representative pictures of cryosections of human vastus lateralis 
muscles stained for the endothelial marker CD31. Muscle biopsies were obtained from 
healthy control female subjects (Ctrl, n = 7, BMI<25 Kg/m2, HOMA<3), obese insulin 
sensitive (Ob-IS, n = 11, BMI>30 Kg/m2, HOMA<3) and obese insulin resistant (Ob-IS, n 
= 11, BMI>30 Kg/m2, HOMA<3) female patients. Scale bar, 100 μm. (B) Capillaries and 
fibers were counted on an average of 4-6 pictures per subject in order to determine 
capillary-to-fiber ratio, the capillary density (cap/mm2), and the mean cross sectional 
fiber area (FCSA, μm2). Data are represented as mean ± SEM. Significantly different 
from Control: ***, P≤0.001, *, P≤0.05. Significant difference between Ob-IS and Ob-IR: 
†††, P≤0.001.  
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Figure A4. Effect of obesity and insulin resistance on human skeletal muscle and 
adipose tissue expression of VEGF-A and TSP-1. Muscle and adipose tissue were 
obtained from female healthy control subjects (Ctrl, n = 10, BMI<25 kg/m2, HOMA<3), 
obese insulin sensitive (OB-IS, n = 12, BMI>30 kg/m2, HOMA<3) and obese insulin 
resistant (Ob-IR, n=9, BMI>30 kg/m2, HOMA>3) female patients. VEGF-A and TSP-1 
mRNA expression were measured using Taqman qPCR, and relative expression 
quantified relative to the housekeeping gene HPRT. Data are shown as mean ± SEM. 
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APPENDIX D 
Angiogenesis Proteome Profiler Array – Average pixel density of all proteins. 
 
Angio-adaptive 
Factor 
Average Pixel Density 
CD90+ (NG) MyoFib (NG) CD90+ (HG) MyoFib (HG) 
Activin A 0.0653916 0.0798531 0.0421883 0.0418316 
ADAMTS-1 0.0023249 0.0055314 -0.0017389 0.0009454 
Angiogenin 0.0216571 0.0461472 0.0174389 0.0366668 
Angiopoietin-1 0.0087775 0.0272204 0.0125073 0.0164285 
Angiopoietin-2 0.0098708 0.0150483 0.0067528 0.0121565 
Angiostatin 0.0031963 0.0028313 0.0064749 0.0088242 
Amphiregulin 0.0032909 0.0034265 0.0019364 0.0010769 
Artemin 0.0068473 0.0069668 0.0088886 0.0041499 
Coag. Factor III 0.0045861 -0.0035386 0.0018962 0.0040672 
CXCL 16 0.0101491 0.0007126 0.0146247 -0.0017930 
DPPIV 0.0783494 0.0225707 0.0452054 0.0078149 
EGF 0.0019119 0.0027829 -0.0008411 0.0003101 
EG-VEGF 0.0153446 0.0078450 0.0035638 0.0156410 
Endoglin 0.0038439 0.0041321 -0.0002889 -0.0036800 
Endostatin 0.0303964 0.0680864 0.0144492 0.0264744 
Endothelin-1 0.0156029 0.0121290 0.0175193 0.0124572 
FGF Acidic 0.0011897 0.0097481 0.0065444 0.0006766 
FGF Basic -0.0034200 -0.0008558 0.0058898 -0.0025317 
FGF-4 -0.0016955 0.0028416 0.0056685 0.0043341 
FGF-7 0.0023758 -0.0014838 -0.0001573 0.0123933 
GDNF 0.0020356 -0.0028623 0.0024411 -0.0011333 
GM-CSF 0.0072675 0.0084575 0.0078463 0.0044375 
HB-EGF 0.0006003 0.0725584 0.0015689 0.0153892 
HGF 0.0186810 0.0011249 0.0090952 0.0046592 
IGFBP-1 0.0310422 0.0425930 0.0154933 0.0240761 
IGFBP-2 0.0736251 0.2468280 0.0689911 0.3332563 
IGFBP-3 0.4755432 0.9773137 0.3972009 0.9855073 
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IL-1β 0.0067655 0.0012681 -0.0033170 -0.0005357 
IL-8 0.0524864 0.1736761 0.0686400 0.0978965 
LAP (TGF-β1) 0.0121102 0.0149223 0.0113809 0.0161635 
Leptin 0.0050718 0.0036870 -0.0018432 -0.0051253 
MCP-1 0.5324866 0.0197446 0.6019196 0.0266398 
MIP-1α 0.0093596 0.0077778 0.0062427 0.0052362 
MMP-8 -0.0015772 -0.0033488 -0.0022692 0.0089031 
MMP-9 0.0284462 0.0204157 0.0208253 0.0232435 
NRG1-β1 -0.0021975 0.0055762 -0.0015232 -0.0054543 
Pentraxin 3 0.3884454 0.1916695 0.4001466 0.1329093 
PD-ECGF -0.0092432 -0.0096929 -0.0067199 -0.0071157 
PDGF-AA 0.0048299 0.0362456 0.0059483 0.0247415 
PDGF-AB/PDGF-BB 0.0011916 0.0109403 0.0061476 0.0101586 
Persephin 0.0103965 0.0109178 0.0070381 0.0094087 
Platelet Factor 4 0.0156375 0.0155193 0.0163710 0.0158872 
PIGF 0.0170328 0.0092512 0.0077567 -0.0010206 
Prolactin -0.0010915 0.0021325 0.0064767 0.0036048 
Serpin B5 -0.0045352 0.0007729 0.0035638 0.0075574 
Serpin E1 0.9368315 0.7497179 0.8758050 0.7069684 
Serpin F1 0.2059035 0.2435516 0.2018589 0.2275393 
TIMP-1 1.8585421 1.6301790 1.9083020 1.3658201 
TIMP-4 -0.0007950 -0.0009645 0.0015451 0.0030335 
Thrombospondin-1 0.6664168 0.6629549 0.7008770 0.5213979 
Thrombospondin-2 0.0040367 0.0238508 0.0104995 0.0341220 
uPA 1.4798492 2.7020231 1.6569882 2.8778939 
Vasohibin 0.0110314 0.0043927 0.0070253 0.0016521 
VEGF 0.1194461 0.2836843 0.1008664 0.1587447 
VEGF-C 0.0053320 0.0041787 0.0024941 -0.0009097 
Reference Spots 1.0029343 0.9330299 1.0511299 1.0835260 
Reference Spots 1.0854860 1.0556779 1.0725495 1.0057719 
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Angiogenesis Proteome Profiler Array – Relative percent change in pixel density  
 
Angio-adaptive 
Factor 
Percent Change in Pixel Density 
MyoFib (NG) vs. 
CD90+ (NG)  
MyoFib (HG) vs. 
CD90+ (HG) 
MyoFib (HG) vs. 
MyoFib (NG) 
Activin A 122 99 52 
ADAMTS-1 238 -54 17 
Angiogenin 213 210 79 
Angiopoietin-1 310 131 60 
Angiopoietin-2 152 180 81 
Angiostatin 89 136 312 
Amphiregulin 104 56 31 
Artemin 102 47 60 
Coag. Factor III -77 214 -115 
CXCL 16 7 -12 -252 
DPPIV 29 17 35 
EGF 146 -37 11 
EG-VEGF 51 439 199 
Endoglin 107 1274 -89 
Endostatin 224 183 39 
Endothelin-1 78 71 103 
FGF Acidic 819 10 7 
FGF Basic 25 -43 296 
FGF-4 -168 76 153 
FGF-7 -62 -7881 -835 
GDNF -141 -46 40 
GM-CSF 116 57 52 
HB-EGF 12087 981 21 
HGF 6 51 414 
IGFBP-1 137 155 57 
IGFBP-2 335 483 135 
IGFBP-3 206 248 101 
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IL-1β 19 16 -42 
IL-8 331 143 56 
LAP (TGF-β1) 123 142 108 
Leptin 73 278 -139 
MCP-1 4 4 135 
MIP-1α 83 84 67 
MMP-8 212 -392 -266 
MMP-9 72 112 114 
NRG1-β1 -254 358 -98 
Pentraxin 3 49 33 69 
PD-ECGF 105 106 73 
PDGF-AA 750 416 68 
PDGF-AB/PDGF-BB 918 165 93 
Persephin 105 134 86 
Platelet Factor 4 99 97 102 
PIGF 54 -13 -11 
Prolactin -195 56 169 
Serpin B5 -17 212 978 
Serpin E1 80 81 94 
Serpin F1 118 113 93 
TIMP-1 88 72 84 
TIMP-4 121 196 -315 
Thrombospondin-1 99 74 79 
Thrombospondin-2 591 325 143 
uPA 183 174 107 
Vasohibin 40 24 38 
VEGF 237 157 56 
VEGF-C 78 -36 -22 
Reference Spots 93 103 116 
Reference Spots 97 94 95 
 
